What clinical trials for biomarkers that are specific for advanced prostate cancer that will make pluvicto more...

I understand you're interested in clinical trials studying biomarkers that could help make Pluvicto (lutetium Lu 177 vipivotide tetraxetan) more effective for advanced prostate cancer. Here is some relevant information from trusted sources:

According to the National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer, Pluvicto is FDA-approved for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) in patients who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. PSMA expression is a key biomarker for determining eligibility for this targeted radioligand therapy.

The American Society of Clinical Oncology (ASCO) states that ongoing clinical trials are evaluating various biomarkers and patient characteristics to better predict response to Pluvicto and optimize patient selection. Some areas of research include:

1. Quantifying PSMA expression levels to determine if higher expression correlates with improved efficacy
2. Studying genomic markers like DNA damage repair gene mutations that may impact response
3. Evaluating other potential predictive markers in the tumor microenvironment

One such trial is the VISION sub-study (NCT03511664), which according to the National Cancer Institute, is analyzing biomarkers in blood and tissue samples to assess their impact on outcomes with Pluvicto in mCRPC.

It's important to discuss your specific case with your oncology team to determine if you may be eligible for any biomarker-driven trials that could help optimize your treatment with Pluvicto or other therapies. They can provide personalized recommendations based on your cancer's features and your overall health.